Hepatic veno-occlusive disease following hematopoietic stem cell transplantation

被引:57
作者
Richardson, P
Guinan, E
机构
[1] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
[3] Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA
关键词
chemotherapy; high-dose; endothelial injury; stem cell transplantation; hematopoietic; veno-occlusive disease; hepatic; prevention and; treatment;
D O I
10.1159/000046590
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The clinical syndrome of hepatic veno-occlusive disease (VOID) is one of the most common and serious complications following hematopoietic stem cell transplantation (SCT). High-dose chemotherapy or chemoradiation therapy in the context of autologous and allogeneic SCT can profoundly injure sinusoidal endothelium and hepatocytes within zone 3 of the liver acinus, producing the clinical syndrome of hepatomegaly and/or right upper quadrant pain with jaundice and fluid retention, typically manifest as weight gain. The incidence is variable and ranges from 10 to 60%. Mild to moderate disease is characterized by eventual complete resolution. In contrast, severe disease frequently results in multiorgan failure and death. The purpose of this review is to discuss the pathophysiology and clinical features of VOID, and the current status and future directions of research for both prevention and treatment. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:57 / 68
页数:12
相关论文
共 121 条
[1]  
Abecasis M, 1999, BONE MARROW TRANSPL, V23, pS222
[2]  
ALLEN JR, 1969, ARCH PATHOL, V87, P279
[3]  
Alvarez R, 2000, Gastroenterol Hepatol, V23, P177
[4]   TRANSFORMING GROWTH-FACTOR-BETA AS A PREDICTOR OF LIVER AND LUNG FIBROSIS AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ADVANCED BREAST-CANCER [J].
ANSCHER, MS ;
PETERS, WP ;
REISENBICHLER, H ;
PETROS, WP ;
JIRTLE, RL .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (22) :1592-1598
[5]  
BAGLIN TP, 1990, BONE MARROW TRANSPL, V5, P439
[6]   THE SYNDROME OF HEPATIC VENOOCCLUSIVE DISEASE AFTER MARROW TRANSPLANTATION [J].
BEARMAN, SI .
BLOOD, 1995, 85 (11) :3005-3020
[7]   Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients [J].
Bearman, SI ;
Lee, JL ;
Baron, AE ;
McDonald, GB .
BLOOD, 1997, 89 (05) :1501-1506
[8]  
BEARMAN SI, 1992, BLOOD, V80, P2458
[9]   VENOOCCLUSIVE DISEASE OF THE LIVER - DEVELOPMENT OF A MODEL FOR PREDICTING FATAL OUTCOME AFTER MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
ANDERSON, GL ;
MORI, M ;
HINDS, MS ;
SHULMAN, HM ;
MCDONALD, GB .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (09) :1729-1736
[10]   DEFIBROTIDE, BY ENHANCING PROSTACYCLIN GENERATION, PREVENTS ENDOTHELIN-1 INDUCED CONTRACTION IN HUMAN SAPHENOUS VEINS [J].
BERTI, F ;
ROSSONI, G ;
BIASI, G ;
BUSCHI, A ;
MANDELLI, V ;
TONDO, C .
PROSTAGLANDINS, 1990, 40 (04) :337-350